NMNH, short for Reduced Beta-Nicotinamide Mononucleotide, refers to the reduced form of NMN. Preclinical studies show that NMNH demonstrates a remarkable 10X surge in NAD+ levels.
EffePharm's UthPeak™ NMNH has completed toxicology and efficacy tests, affirming its safety and health potential in the dietary supplement market. Our animal tests highlight its anti-aging, anti-fatigue, and cardiovascular health benefits. Clinical trials on humans are currently underway. Partnering with Double Wood, the first UthPeak™ NMNH product has launched on Amazon. Download the flyer below to learn more.
